[go: up one dir, main page]

ES2087156T3 - Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus. - Google Patents

Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.

Info

Publication number
ES2087156T3
ES2087156T3 ES90909877T ES90909877T ES2087156T3 ES 2087156 T3 ES2087156 T3 ES 2087156T3 ES 90909877 T ES90909877 T ES 90909877T ES 90909877 T ES90909877 T ES 90909877T ES 2087156 T3 ES2087156 T3 ES 2087156T3
Authority
ES
Spain
Prior art keywords
viruses
plasma
blood product
inactivation
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90909877T
Other languages
English (en)
Inventor
Michael E Hrinda
Alisa Rose D
George Crissman Tarr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rorer International Overseas Inc
Original Assignee
Rorer International Overseas Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer International Overseas Inc filed Critical Rorer International Overseas Inc
Application granted granted Critical
Publication of ES2087156T3 publication Critical patent/ES2087156T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

ESTA INVENCION PROPORCIONA UNA COMBINACION, LIBRE DE FALLOS, DE MEDIOS FISICOS Y QUIMICOS PARA RECUPERAR UN PRODUCTO SANGUINEO QUE CONTENGA UNA PROTEINA SANGUINEA LABIL LIBRE DE VIRUS SIN PROVOCAR UNA DESNATURALIZACION PROTEINICA. AL PRODUCTO SANGUINEO SE LE PONE EN CONTACTO CON UNA CANTIDAD SUFICIENTE DE UN DESINFECTANTE QUIMICO SELECCIONADO, PREFERIBLEMENTE, TRIOCIANATO DE SODIO EN COMBINACION CON UN PROCESO FISICO, PREFERIBLEMENTE, ULTRAFILTRACION. EL PRODUCTO SANGUINEO PUEDE SER PLASMA, SUERO, CONCENTRADO DE PLASMA, CRIOPRECIPITADO, CRIOSUPERNATANTE, PRECIPITADO DE FRACCIONAMIENTO DE PLASMA O SUPERNATANTE DE FRACCIONAMIENTO DE PLASMA QUE CONTENGAN VIRUS COMO EL DE LA HEPATITIS O EL VIRUS DE LA INMUNODEFICIENCIA HUMANO.
ES90909877T 1989-06-15 1990-06-13 Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus. Expired - Lifetime ES2087156T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36685589A 1989-06-15 1989-06-15

Publications (1)

Publication Number Publication Date
ES2087156T3 true ES2087156T3 (es) 1996-07-16

Family

ID=23444851

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90909877T Expired - Lifetime ES2087156T3 (es) 1989-06-15 1990-06-13 Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.

Country Status (9)

Country Link
US (1) US5300433A (es)
EP (1) EP0431129B1 (es)
JP (1) JP3297433B2 (es)
AT (1) ATE138575T1 (es)
CA (1) CA2034489C (es)
DE (1) DE69027187T2 (es)
DK (1) DK0431129T3 (es)
ES (1) ES2087156T3 (es)
WO (1) WO1990015613A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
AU6653094A (en) * 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
EP0767675A4 (en) * 1995-04-10 1998-08-05 Baxter Int USE OF CROSS-LINKED HEMOGLOBIN IN THE TREATMENT OF SUBARACHNOIDAL BLEEDING
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6747132B2 (en) * 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
CA2476999C (en) * 2002-02-22 2015-09-15 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
WO2004024283A2 (en) * 2002-09-13 2004-03-25 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
DE602005009677D1 (de) * 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
WO2006023774A2 (en) * 2004-08-20 2006-03-02 Imquest Biosciences, Inc. Plasma or serum fraction for treatment and prevention of viral infections and related conditions
PL2278002T3 (pl) 2005-07-29 2017-12-29 Abbott Laboratories Gmbh Pankreatyna o zmniejszonej zawartości wirusowej
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
WO2012069474A2 (en) * 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
RS57397B8 (sr) 2011-06-10 2020-01-31 Univ Oregon Health & Science Cmv glikoproteini i rekombinantni vektori
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS61500226A (ja) * 1983-10-28 1986-02-06 ニュ−・イングランド・メディカル・センタ−・ホスピタルズ・インコ−ポレ−テッド コンホメ−ション特異性抗体を用いる血液凝固タンパク質の精製および単離法
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) * 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
DD264137A1 (de) * 1987-09-22 1989-01-25 Univ Leipzig Mittel zur bekaempfung von viren in kulturpflanzen

Also Published As

Publication number Publication date
ATE138575T1 (de) 1996-06-15
US5300433A (en) 1994-04-05
JP3297433B2 (ja) 2002-07-02
DK0431129T3 (da) 1996-06-17
CA2034489C (en) 1996-07-16
EP0431129A4 (en) 1992-03-11
EP0431129B1 (en) 1996-05-29
CA2034489A1 (en) 1990-12-16
DE69027187D1 (de) 1996-07-04
JPH04501429A (ja) 1992-03-12
DE69027187T2 (de) 1996-10-31
EP0431129A1 (en) 1991-06-12
WO1990015613A1 (en) 1990-12-27

Similar Documents

Publication Publication Date Title
ES2087156T3 (es) Metodos para la inactivacion de virus en composiciones farmaceuticas contaminadas por virus.
ATE54828T1 (de) Behandlung von auf einer festen phase adsorbierten biologischen und pharmazeutischen produkten mit viren und pyrogenen inaktivierenden agenzien.
DK552684D0 (da) Desulfatohirudiner samt deres fremstilling og anvendelse
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
DK0722344T3 (da) Fremgangsmåde til virusinaktivering i nærvær af en polyether og et middel
KR950010898A (ko) 재조합 사람 혈청 알부민 약제학적 제제의 멸균법
DE68929388D1 (de) Aus Harn isolierte antikoagulierende Verbindung
ATE78397T1 (de) Verwendung von p-chlorophenoxyazetat von n,ndimethylbiguanidzur behandlung von neuropathien und nervendegeneration.
DE69230643D1 (de) Methode zur behandlung von viralen infektionen
ATE286407T1 (de) Verfahren zur inaktivierung von pathogenen mittels breitspektrum-pulslicht
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
ES2149791T3 (es) Procedimiento para la inactivacion de virus en preparaciones de proteinas.
ATE115863T1 (de) Verwendung eines immunglobulinhaltigen präparates zur prophylaxe und therapie von aids beim menschen.
DK82892D0 (da) Anvendelse af braadgifte fra bier og hvepse til fremstilling af laegemidler til behandling af infektioner
YU57994A (sh) Postupak za inaktiviranje virusa u prisustvu polialkilenglikola i farmaceutski preparat dobijen tim postupkom
EP0686694A1 (en) Use of azoles as virucidal agents in solutions of biologically active proteins
ATE88752T1 (de) Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole.
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
Nazari et al. Virus reduction of human plasma-derived biological medicines
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
EP0330647A3 (en) The use of chymotrypsin for the inactivation of prekallikrein activator
Herring Grifols’ factor IX concentrates: new findings in biochemical characteristics and safety profiles.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0431129

Country of ref document: ES